The California HIV/AIDS Research Program (CHRP) is funding the largest demonstration project of its kind in the US, to determine the acceptability, utilization, adherence, and pharmacokinetics of HIV pre-exposure prophylaxis (PrEP) medication among transgender persons to promote their health and protect their lives. As researchers, participants and healthcare providers explain here, the three CHRP-supported studies across the state use different techniques, such as providing PrEP and hormonal therapy together at a single clinic visit, offering in-depth pharmacokinetic analyses on how the two treatments interact, or creating a custom text messaging app to communicate with providers and offer peer support. Information on how to enroll in the University of California-affiliated studies is included. Series: "UCTV Prime" [Public Affairs] [Health and Medicine] [Show ID: 33176]